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Macrophages activated through Toll receptor triggering in-
crease the expression of theA2A andA2B adenosine receptors. In
this study, we show that adenosine receptor activation enhances
LPS-induced pfkfb3 expression, resulting in an increase of the
key glycolytic allosteric regulator fructose 2,6-bisphosphate and
the glycolytic flux. Using shRNA and differential expression of
A2A and A2B receptors, we demonstrate that the A2A receptor
mediates, in part, the induction of pfkfb3 by LPS, whereas the
A2B receptor, with lower adenosine affinity, cooperates when
high adenosine levels are present. pfkfb3 promoter sequence
deletion analysis, site-directed mutagenesis, and inhibition by
shRNAs demonstrated that HIF1 is a key transcription factor
driving pfkfb3 expression following macrophage activation by
LPS, whereas synergic induction of pfkfb3 expression observed
with the A2 receptor agonists seems to depend on Sp1 activity.
Furthermore, levels of phospho-AMPkinase also increase, argu-
ing for increased PFKFB3 activity by phosphorylation in long
term LPS-activated macrophages. Taken together, our results
show that, in macrophages, endogenously generated adenosine
cooperates with bacterial components to increase PFKFB3
isozyme activity, resulting in greater fructose 2,6-bisphosphate
accumulation. This process enhances the glycolytic flux and
favorsATPgeneration helping to develop andmaintain the long
term defensive and reparative functions of the macrophages.
Macrophages are key cellular components of the innate
immune system.They are present in all body tissues,where they
normally assist in guarding against invading pathogens, and
regulate normal cell turnover and tissue remodeling. Macro-
phages discriminate between pathogens and self through sig-
nals triggered by Toll-like receptors, which recognize different
pathogen components, such as LPS, lipoproteins, or dsRNA,
among others (1). Activation of most Toll receptors triggers a
complex signaling pathway involving the transcription factor
NFB (2), which, upon activation, induces the expression of
multiple genes implicated in the inflammatory response,
including cytokines, effector enzymes such as iNOS and
COX-2, and adhesion molecules that enable macrophages to
mount an immediate attack against pathogens (1).
The activation ofmacrophages is dependent on various ener-
gy-requiring pathways, mainly glycolysis (3). To reach the
inflammation sites, macrophages recruited from the blood
need to move against oxygen gradients (4). Macrophages and
other cells of the innate immune system need to adapt to this
special condition tomaintain viability and activity. Therefore, a
high glycolytic flux is essential for macrophage activity in these
conditions (5, 6).
Unlike almost all other cells, macrophages and myeloid cells
do not typically shift to mitochondrial respiration, even in
highly oxygenated environments. Indeed, glycolytic inhibitors
have been shown to greatly reduce both the cellular ATP con-
centration and the functional activity of macrophages, whereas
inhibitors ofmitochondrial respiration have shownno effect on
the inflammatory response (5, 7, 8). Macrophages activated by
LPS increase the levels of lactate production (5), a marker of
enhanced glycolytic function. Glycolytic flux is mainly con-
trolled by 6-phosphofructo-1-kinase (9), with fructose 2,6-bis-
phosphate (Fru-2,6-P2)2 being its most powerful allosteric acti-
vator. This property confers to this metabolite a key role in the
control of the glycolytic pathway (10). 6-Phosphofructo-2-ki-
nase/fructose-2,6-bisphosphatase (PFK-2) is the bifunctional
enzyme that catalyzes the synthesis and degradation of Fru-
2,6-P2 and, hence, critically regulates the glycolytic rate under
multiple pathophysiological conditions (10). Different PFK-2
isozymes generated from four genes (pfkfb1–4) have been iden-
tified in mammalian tissues (11). Proliferative and transformed
cells and macrophages express the PFKFB3 isozyme, which is a
product of the pfkfb3 gene (12–16). This isoform presents the
highest kinase-bisphosphatase activity ratio, thus generating
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the highest Fru-2,6-P2 levels. PFKFB3 isozyme expression is
induced by proinflammatory stimuli, hypoxia, and growth fac-
tors in different cells (12, 17), and the protein is degraded
through the ubiquitin-proteasome proteolytic pathway (18).
pfkfb3mRNA containsmultiple copies of the AUUUA instabil-
ity motif in its 3-nontranslated region (14). This sequence
motif confers both enhanced translation and instability to the
mRNAmolecule, and thus it plays an important role in regulat-
ing the half-life of the gene product in different physiological
conditions. Analysis of the 5 pfkfb3 promoter sequence has
revealed the presence of putative consensus binding sites for
different transcription factors, which could play important
roles in the regulation of pfkfb3 gene expression. Binding of the
transcription factor HIF1 seems critical for the hypoxia-depen-
dent induction of this gene (17).
Althoughmacrophage function is essential for the successful
destruction of pathogens, failure to controlmacrophage activa-
tion or prolonged or inappropriate inflammatory processes will
lead to unacceptable levels of collateral damage to surrounding
cells.Multiplemechanisms controlling the extension ofmacro-
phage activation have been described (19). In the last years,
adenosine has been shown to modulate the inflammatory
response by limitingmacrophage activation (20, 21). Utilization
of ATP during periods of high metabolic activity leads to an
increased concentration of intracellular adenosine that can be
secreted through nucleoside transporters. Anothermajor path-
way contributing to high extracellular adenosine concentration
during metabolic stress is the release from the cells of its pre-
cursor adenine nucleotides (ATP, ADP, and AMP), followed by
extracellular degradation to adenosine. Adenosine accumula-
tion is limited by its catabolic degradation to inosine and uric
acid (20). Neutrophils and endothelial cells release large
amounts of adenosine at sites of inflammation and infection.
Activated macrophages can also serve as a major source of
extracellular adenosine via ATP production (22). Adenosine
acts at the cell surface through four G protein-coupled adeno-
sine receptors (A1, A2A, A2B, and A3). Lower concentrations of
adenosine activate the high affinity A1 and A2A receptors,
whereas a high adenosine concentration also stimulates the low
affinity A2B and A3 receptors (20). Adenosine receptors
expressed on monocytes and macrophages allow these cells to
detect stressful conditions and modulate their cellular func-
tions to adapt to their microenvironment. Activation of A2A
receptors in macrophages has been related to the anti-inflam-
matory effects of adenosine, such as the down-regulation of
TNF production (20, 23), and to a macrophage-regenerative
phenotype, as suggested by the production of VEGF (24, 25).
The use of A2A receptor-deficient mice as a model of acute
inflammation has demonstrated clearly the role of these recep-
tors in immunosuppression (26–28).
In this study, we show that Toll receptor agonists and aden-
osine, through its A2A and A2B receptors, cooperate to increase
glycolytic flux inmacrophages by favoring the expression of the
PFKFB3 isozyme. We have found that the Toll-4 receptor ago-
nist LPS increases the expression of A2A and A2B receptors in
macrophages, augmenting its sensibility to adenosine. We also
show here that although LPS-dependent induction of HIF1 is
essential for pfkfb3 expression, the synergic induction of pfkfb3
expression observed with A2R agonists critically depends on
the transcription factor Sp1.
EXPERIMENTAL PROCEDURES
Chemicals—Adenosine, A2A receptor agonist 2-p-(2-car-
boxyethyl) phenethylamino-5-N-ethylcarboxamidoadenosine
(CGS-21680), A2 receptor agonist 5-(N-ethylcarboxamido)ad-
enosine (NECA), A2B receptor antagonist 8-[4-[4-cya-
nophenyl)carbamoylmethyl)oxy]phenyl]-1,3-di(n-propyl)xan-
thine (MRS 1754), deferoxamine, and CoCl2 were purchased
from Sigma. A2A receptor antagonist 4-(2-triazolo(2,3-)tri-
azin-ylamino)ethyl)phenol (ZM 241385) was purchased from
Tocris Cookson. Toll receptors agonists, LPS from Salmonella
typhimurium, poly(I:C), LTA-SA, and CpG were from Sigma.
Serum and culture medium were acquired from BioWhittaker
(Walkersville, MD). Electrophoresis equipment and reagents
were purchased from Bio-Rad.
Cell Culture—Elicited peritoneal macrophages were ob-
tained from male mice 4 days after intraperitoneal inoculation
of 1ml of sterile 10% (w/v) thioglycollate. Cells were seeded at a
density of 1  105/cm2 in RPMI 1640 medium supplemented
with 10% heat-inactivated FCS and 50 g/ml each gentamicin,
penicillin, and streptomycin. Raw 264.7 cells were subcultured
at a density of 6–8  104/cm2 in RPMI 1640 medium supple-
mented with 2 mM glutamine, 10% FCS, and the aforemen-
tioned antibiotics. After 2 days in culture, the medium was
replaced by RPMI 1640 containing 5% FCS, and the cells were
used in the following 24 h. Bone marrow-derived macrophages
were obtained by flushing the femurs from IRF-3/ or IRF-
3/ mice with DMEM containing 10% inactivated fetal calf
serum (FCS), 2 mM L-glutamine, 100 units/ml penicillin, 100
g/ml streptomycin (all from Sigma) and subsequent culture in
the samemedium supplemented with 15% of L929 supernatant
as a source of macrophage colony-stimulating factor.
Stable cell lines expressing dominant active forms of IB
(Raw-IB-DA) have been described elsewhere (29). Human
monocytes were isolated from the blood of healthy donors by
centrifugation on Ficoll-PaqueTM PLUS (Amersham Biosci-
ences) following previously reported protocols (30). Hypoxia
simulation conditions were achieved by growing cells in RPMI
1640 medium supplemented with 200 M deferoxamine or 200
M CoCl2.
Metabolite Determinations—Fru-2,6-P2 was determined as
described previously (31). The concentration of lactate was
measured enzymatically in neutralized HClO4 extracts, as
described previously (32). Biochemicals used for these mea-
surements were from Roche Applied Science. ATP levels were
determined by following the Sigma ATP bioluminescent
somatic cells assay kit.
Generation of Plasmids and Mutant Constructs—Plasmids
pCMV-SPORT6-A2AR and pCMV-SPORT6-A2BR were pur-
chased fromATCC. shRNA plasmid for mouse A2AR and A2BR
and shRNA plasmid for mouse HIF1 and C/EBP and -were
purchased from SABiosciences; Sp1 siRNAs were from
Ambion. p-GL2-basic luciferase expression vectors containing
various lengths of 5-flanking regions from the human pfkfb3
gene promoter and an HIF1-luciferase reporter gene have been
described previously (17, 33).
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Mutated pfkfb3 gene promoter constructs were prepared
by gene synthesis following instructions included in the
QuikChange (Stratagene) site-directed mutagenesis kit. For-
ward oligonucleotides used in binding site mutations (repre-
sented in boldface type) were as follows: SP1 (110 CCC ACG
TGGAAGGGTATTGGGACCCAAGGAATGCG75 and
83 ATG CGG CCC GTA TCG AGG CTG ACG TAG CGT
C48);HIF (121CCACCCTCCTCCCCTGGTGGAAGG
GGG CTG G90); cEBP (872 CCC TCG ACT TAG GCT
GTGAAT TGCAGA TCGAAA TGGG835). Mutated sites
were confirmed by DNA sequencing. All plasmid DNA was
purified using EndoFree columns (Qiagen).
Cell Transfections—Subconfluent Raw 264.7 cells were
seeded in 12-well plates and transfected on the following day
with 600 ng of plasmid DNA by using the FuGENE 6 reagent
(Roche Applied Science), according to the manufacturer’s rec-
ommendations. A -galactosidase expression vector was used
as an internal control for transfection efficiency. Luciferase and
-galactosidase activities were measured by using a commer-
cial kit (Promega). To evaluate shRNA efficiency, Raw cells
were cotransfected with GFP, and GFP cells were analyzed by
Western blot.
RNA Extraction and Analysis of Gene Expression by Quanti-
tative RT-PCR—Total RNA was extracted (from 2 to 4  106
cells) by following the Qiagen RNA purification method. For
reverse transcription (RT)-PCR, cDNA was generated from 1
g of total RNAby using the RevertAidTMHMinus First Strand
(Fermentas) cDNA synthesis kit. Quantitative RT-PCR was
performed following the SYBR Green protocol from Applied
Biosystems. Amplification of the housekeeping gene GADPH
was used as a quality and loading control. The forward and
reverse primers, respectively, used for quantitative PCR ampli-
fication were as follows: GADPH, 5-AAC TTT GGC ATT
GTG GAA GG-3 and 5-GGA TGC AGG GAT GAT GTT
CT-3; A1R, 5-TTC TGCGTC CTGGTA TGT GAC CAA-3
and 5-GCA GAG CCC AGC TTT GGA AAT TGA-3; A2AR,
5-ACA CGC CTC AGC AAG ACA CAA T-3 and 5-AAA
GCC AGC GTT GTG CAT CT-3; A2BR, 5-ATT CGC GTC
CCG CTC AGG TAT AAA-3 and 5-AAT CCA ATG CCA
AAG GCA AGG ACC-3; A3R, 5-ACG CGA ACT CCA TGA
TGA ACC CTA-3 and 5-ACT GAT ACC ACA TGC GAA
GGC AGA-3; HIF1, 5-CTA CTG CAG GGT GAA GAA
TTACTCAGAGC-3 and 5-GTGCAATTGTGGCTACCA
TGTACTGCTG-3; PFKFB3, 5-TCT AGAGGAGGTGAG
ATC AG-3 and 5-CCT GCC ACT CTT ATC TTC TG-3;
iNOS, 5-GCA AGT CCA AGT CTT GCT TGG-3 and
5-GGT TGA TGA ACT CAA TGG CAT CAT G-3; TNF,
5-GAC GTG GAA CTG GCA GAA GAG-3 and 5-AAG
CAGGAATGAGAAGAGGCTG-3; GLUT1, 5-GGGCAT
GTG CTT CCA GTA TGT-3 and 5-ACG AGG AGC ACC
GTGAAGAT3; phosphoglycerate kinase, 5-CTGTGGTAC
TGA GAG CAG CAA GA-3 and 5-CAG GAC CAT TCC
AAA CAA TCT G-3; and VEGF, 5-AGT CCC ATG AAG
TGA TCA AGT TCA-3 and 5-ATC CGC ATG ATC TGC
ATG G-3.
Preparation of Cell Extracts andWestern Blot Analysis—Ad-
herent macrophages (1–3 106 cells) were washed twice with
ice-cold PBS, scraped off the dishes, and collected by centrifu-
gation. Cell pellets were homogenizedwith 200l of lysis buffer
(20 mMTris-HCl, pH 7.8, 0.4 M NaCl, 5 mMMgCl2, 10 mMKCl,
0.5 mM EGTA, 1 mM phenylmethylsulfonyl fluoride, 0.5 mM
dithiothreitol, 10 M leupeptin, 10 mM sodium fluoride, 1 mM
sodium vanadate, and 0.5% Nonidet P-40). Cells were gently
vortexed for 20 min at 4 °C, and following centrifugation at
8,000  g for 15 min, the supernatants were stored at 80 °C
(total extracts). Sample protein concentrations were deter-
mined by using the detergent-compatible protein reagent from
Bio-Rad. Samples containing equal amounts of protein were
boiled in denaturing buffer (250 mM Tris-HCl, pH 6.8, 2% SDS,
10% glycerol, 2% -mercaptoethanol) and size-separated by
loading 80–120 g of total cell extracts per well in a polyacryl-
amide gel in the presence of 10% SDS. The gels were transferred
to HybondTM-C extra nitrocellulose membranes (Amersham
Biosciences), which were then processed according to the rec-
ommendations provided by the antibody suppliers.
An antibody against PFKFB3 was obtained as described pre-
viously (16). Anti-HIF1 antibody was purchased from R&D
Systems. Anti-phospho-AMPK--Thr-172 or anti-AMPK-
antibodies were purchased from Cell Signaling. -Tubulin was
detected using anti--tubulin antibody purchased from Sigma.
Anti-C/EBP, anti-C/EBP, anti-Sp1, anti-Ser(P), anti-A2AR,
and anti-A2BR antibodies were purchased from Santa Cruz
Biotechnology. Proteinswere detected byECL (AmershamBio-
sciences). In each assay, several film exposure times were used
to avoid film saturation.
Data Analysis—The number of experiments performed and
analyzed is indicated in the corresponding figure legends. Sta-
tistical differences (p 0.05) between mean values were deter-
mined by one-way analysis of the variance, followed by Stu-
dent’s t test.
RESULTS
Toll Receptor Agonists Increase pfkfb3 Gene Expression in
Macrophages—Macrophage activation with LPS increased the
expression of pfkfb3 in both murine peritoneal macrophages
and human monocytes/macrophages (Fig. 1A). Maximal
mRNA levels were reached about 6 h after LPS triggering and
decreased to near control levels 24 h after stimulation. These
results agree with previous observations in human monocytes
(14). Increased PFKFB3 isozyme levels could be detected for at
least 24 h (Fig. 1B), and in accordance with that, elevated levels
of the metabolite Fru-2,6-P2 were detected 8 h after macro-
phage activation by LPS and could be observed for 24 h (Fig.
1C).We have extended these initial studies and confirmed that,
besides LPS, other Toll receptor agonists, such as viral double-
stranded RNA and bacterial lipopeptides, also increase pfkfb3
gene expression (Fig. 1D). These data indicate that up-regula-
tion of pfkfb3 is a common process in the course ofmacrophage
activation.
Adenosine Cooperates with LPS to Increase pfkfb3 Gene
Expression—As macrophage activation by pathogens increases
ATP consumption (34), and highmetabolic activity leads to the
liberation of adenosine (35), we explored whether adenosine
could affect pfkfb3 expression and thus modulate the glycolytic
flux in activated macrophages. Adenosine, the A2AR-specific
agonist CGS1680, or the A2R-nonspecific agonist NECA ex-
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erted little effect by themselves in resting macrophages, but
they all cooperated with LPS to increase pfkfb3 expression (Fig.
2, A and B). Increased levels of the metabolite Fru-2,6-P2 were
found also in macrophages treated with LPS and adenosine or
A2 receptor agonists (Fig. 2C).
In the few last years, adenosine has been shown to modulate
the inflammatory response by limiting macrophage activation
through the A2A receptors and to favor the development of an
angiogenic phenotype (20, 21). To assess whether adenosine
and the other A2R agonists worked correctly in our cells, we
evaluated their effects on TNF, VEGF, and iNOS expression
after induction with LPS. In agreement with previous reports
(25, 36), TNF expression was repressed in macrophages
treated with adenosine or CGS1680, whereas LPS-induced
iNOS and VEGF expression was increased (supplemental Fig.
1). Therefore, taken together, these results identify, for the first
time, pfkfb3 as a gene whose expression is synergistically up-
regulated by LPS and adenosine, leading also to a synergistic
effect on Fru-2,6-P2 production.
Toll-4 Signaling Increases the Expression of A2A and A2B
Receptors—A previous report has shown that adenosine recep-
tors are modulated by LPS (37). We also report here a potent
increase in the expression of A2A and A2B receptors in murine
macrophages activated with LPS (Fig. 3A). The mRNA levels of
A1 andA3 adenosine receptors decreased in this condition (Fig.
3A), as described previously (37). Although the induction rela-
tive to basal levels of A2BR by LPS was lower than that observed
for A2AR (Fig. 3, A and B), basal expression levels of A2BR in
control macrophages were higher than the levels of A2AR (data
not shown). Both A2A and A2B receptors were induced tran-
siently and rapidly by LPS, reaching maximal mRNA levels 4 h
after treatment and diminishing to basal levels in a short period
of time (Fig. 3B).
We have also observed that A2A receptor induction by LPS is
highly dependent on NFB activation, as Raw-IB-SR cells,
which overexpress the super-repressor IB (unable to
undergo phosphorylation and degradation and thereforemain-
taining low levels of NFB activity), showed a drastic reduction
in the expression levels of A2A induced by LPS (Fig. 3C). How-
ever, A2B receptor expression was only slightly diminished in
this cell line (Fig. 3C). We also evaluated the contribution of
IRF-3, another transcription factor directly activated by LPS, to
A2 receptor expression, in IRF3/ and IRF3/ bonemarrow-
derived macrophages activated by LPS. Expression of the A2A
receptor was not affected by the lack of IRF3; however, A2B
receptor expression was significantly diminished (supplemen-
tal Fig. 2). Taken together, these results show that different
signaling events control the induction by LPS of A2A and A2B
receptors in murine macrophages.
Adenosine Cooperates with LPS to Increase pfkfb3 Promoter
Activity—To investigate the mechanism responsible for the
increased expression of pfkfb3 in macrophages activated by
LPS, we studied both in the absence or in the presence of aden-
osine or adenosine receptor agonists, the activity of the human
pfkfb3 promoter, previously characterized (17). In our studies,
we used Raw 264.7 cells, which conserve the pfkfb3 expression
pattern observed in bone marrow-derived macrophages, peri-
toneal macrophages, and human monocyte/macrophages
when treated with LPS (data not shown). We transfected this
cell line with a construct in which luciferase expression was
driven by a 3,566-bp fragment from the human pfkfb3 pro-
moter. As shown in Fig. 4A, adenosine, CGS1680, or NECA by
themselves exerted little effect on pfkfb3 promoter activity, but
they all cooperated with LPS to increase its effect. The activity
of the pfkfb3 promoter increased about 15-fold by LPS alone, an
induction level similar to that observed with the endogenous
pfkfb3 gene in Raw 264.7 cells (data not shown) or human
monocytes/macrophages stimulated by LPS (Fig. 1A) but
higher than that observed in LPS-activated murine peritoneal
macrophages (about 4-fold, Figs. 1 and 2). Activation of A2
receptors enhanced the promoter activity induced by LPS by
2-fold, thus reaching total induction levels close to 30-fold.
This promoter behavior was coherent with the increased
expression levels of the endogenous pfkfb3 gene observed in
FIGURE 1. Toll receptor agonists increase pfkfb3 gene expression in macrophages. A, quantitative RT-PCR analysis of pfkfb3 mRNA levels in peritoneal
murine macrophages and human monocytes/macrophages activated for different times with the TLR4 agonist LPS (100 ng/ml). B, Western blot analysis of
PFKFB3 protein. C, Fru-2,6-P2 levels in peritoneal macrophages activated for different times with LPS. D, expression of pfkfb3mRNA analyzed by RT-PCR after
triggering macrophages with TLR3 (poly(I:C) 200 ng/ml), TLR2 (LTA-SA 2 g/ml), or TLR9 (CpG 500 ng/ml) agonists for 6 h. Results represent the mean S.D.
of at least three independent experiments. *, p  0.05 versus control cells (A, C, and D) or correspond to a representative experiment out of three (B). a.u.,
arbitrary units.
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macrophages (Fig. 2A) and Raw 264.7 cells (data not shown)
treated with LPS or/and A2 receptor agonists.
pfkfb3 expression is induced in different cell types by hypoxia
(17). We evaluated the effect of two hypoxia mimics, cobalt
chloride (CoCl2) and the iron chelator deferoxamine, in the
activity of the human pfkfb3 promoter in macrophages. Pro-
moter activity increased in both cases by about 5-fold, an
induction level lower than that observed with LPS alone or
LPS with A2 receptor agonists. No cooperation between
hypoxia mimics and adenosine receptor agonists was
observed (data not shown).
We studied theDNA regions required for LPS and adenosine
to increase pfkfb3 promoter activity by using a series of pro-
moter constructs (see promoter diagram shown in Fig. 4B) con-
taining successive deletions from the 5 end, as described pre-
viously (17). For each construct, the fold increase in luciferase
activity, elicited by either LPS alone or together with NECA,
was determined over basal luciferase activity. As shown in Fig.
4C, 5 deletion mutants revealed that sequences between
3,566 and148 from the transcription start site did not sub-
stantially affect induction of the pfkfb3 gene promoter by LPS
and NECA, although some variations in inducibility were
observed. In contrast, both effects were completely abolished
by deleting the region between positions148 and50. These
results show that sequences between 148 and 50 are suffi-
cient for LPS and A2R agonist induction of the pfkfb3 gene
promoter.
Previous studies have identified two proximal hypoxia-re-
sponse element sequences (HRE) between nucleotides 1,269
and 1,297 of the pfkfb3 gene promoter (17). This region is the
major hypoxia-responsive region of this gene, and it is essential
FIGURE 2. Adenosine receptor agonists modulate LPS-induced pfkfb3
gene expression inmacrophages. A, quantitative RT-PCR analysis of pfkfb3
mRNA expression in peritoneal macrophages treated for 6 h with LPS (100
ng/ml), adenosine (10 or 100 M), the specific A2 receptor agonist CGS21680
(2 M), or the nonselective A2 receptor agonist NECA (10 M). B, analysis of
PFKFB3 expression by Western blot performed with extracts from peritoneal
macrophages treated for 12 or 24 hwith the same concentrations as above of
the indicated agents. A representative experiment is shown. C, Fru-2,6-P2
levels in macrophages treated for 12 h as in A. Results represent the mean
S.D. of at least three independent experiments. *, p 0.05 versus control cells.
#, p 0.05 versus LPS-treated cells. a.u., arbitrary units.
FIGURE 3. LPS increases the expression of A2 receptors in macrophages.
A,RT-PCRanalysis of the four adenosine receptors inperitonealmacrophages
treated with LPS (100 ng/ml) for 4 h. B, time course of A2A and A2B receptor
expression in macrophages treated with LPS for the indicated times. C, anal-
ysis by quantitative RT-PCR of A2A and A2B receptor expression in control or
Raw 264.7 cells expressing the super-repressor protein IB (Raw-IB-SR),
4 h after treatment with LPS. Results represent the mean  S.D. of at least
three independent experiments. a.u., arbitrary units.
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for the hypoxia-induced transcription of the pfkfb3 gene pro-
moter in macrophages, as showed at the right panel of Fig. 4C.
Accordingly to these data, some differences could be appre-
ciated between pfkfb3 gene promoter induction by LPS/A2R
agonists and by hypoxiamimics. First, the level of inductionwas
higher with LPS than with hypoxia mimics in macrophages.
The second difference resided on the sequences responsible for
the induction. Stimulation of the pfkfb3promoter by LPS essen-
tially depended on proximal promoter sequences from position
148 to50,whereas induction by hypoxiamimicswasmainly
observed in constructs containing the region between nucleo-
tides 1,269 and 1,297.
Sequence analysis of the proximal pfkfb3 promoter (148
nucleotides) revealed two binding sites for the transcription
factor Sp1 (starting at 72 and 97 nucleotides, respectively)
and oneHRE sequence (107 nucleotides) (Fig. 4B). As shown in
Fig. 4D, site-directed mutagenesis of the Sp1 transcription fac-
tor-binding sites revealed that Sp1 is a key protein for adenosine
cooperationwith LPS in the induction of pfkfb3promoter activ-
ity, for each one of the Sp1-binding site mutations are individ-
ually sufficient to eliminate the adenosine-dependent induc-
tion of the pfkfb3 promoter without affecting induction by LPS.
However, mutation of the HRE-binding site completely abol-
ishes pfkfb3 promoter induction by LPS alone, although LPS in
combination with the A2 receptor agonist NECA still results in
a little induction. These results point at HIF proteins as being
responsible for LPS-dependent induction of the pfkfb3 pro-
moter (Fig. 4D).
Analysis of the Transcription Factors Involved in pfkfb3
Induction by LPS/A2R Agonists—In addition to Sp1 and HRE,
multiple binding sites for relevant transcription factors have
been previously identified in the pfkfb3 gene promoter,
including NFB, C/EBP, EGR-1, and estrogen receptor-
binding elements, among others (Fig. 4B) (17). To identify
additional transcription factors that could modulate pfkfb3
induction by LPS/A2R agonists, we analyzed the effect of LPS
and adenosine/NECA in the activity of proteins potentially
capable of binding to specific pfkfb3 promoter sequences and
related to the LPS or the adenosine response. Reporter con-
structs carrying binding sites for HIF1, NFB, C/EBP, Sp1,
and EGR-1 were transfected into Raw 264.7 cells, which were
stimulated afterward with LPS, NECA, or both. The results
showed that the activity of HIF1, C/EBP, and Sp1 reporter
constructs increased upon activation with LPS, and this
activity was enhanced by the addition of NECA (Fig. 5A). On
the contrary, NFB activity increased with LPS, but it was
FIGURE 4. Specific regions of the pfkfb3 promoter mediate its transcriptional induction by LPS and further up-regulation by adenosine and A2
receptor agonists. A, Raw 264.7 cells were transiently cotransfected with a pGL2-basic luciferase expression vector, containing 3,566 bp of the human pfkfb3
gene promoter, and a -galactosidase expression vector. Cells were activated for 18 hwith LPS (100 ng/ml) and/or adenosine (Ado) (100M), CGS21680 (CGS)
(2 M), or NECA (10 M), or treated with deferoxamine (DFO) (200 M) or CoCl2 (200 M). Transfections were performed in triplicate. Results represent the
mean S.D. of the luciferase activity determined in at least three independent transfection experiments. *, p 0.05 versus LPS treatment; #, p 0.05 versus
control. B, schematic representation of the pfkfb3 promoter with its putative regulatory elements. C, Raw 264.7 cells were transiently transfected with
pGL2-basic luciferase expression vectors containing various lengths of the human pfkfb3 gene promoter 5-flanking region and a -galactosidase expression
vector as a transfection control. Cells were activated for 18 h with LPS or LPS plus NECA or treated with deferoxamine (DFO) or CoCl2. *, p 0.05 versus LPS
treatment; #, p 0.05 versus control. D, activity of pfkfb3minimal promoter following site-directed mutations of the HRE and the two Sp1-binding sites. In all
cases, transfections were performed in triplicate. Results represent themean S.D. of at least three independent transfection experiments. *, p 0.05 versus
LPS plus NECA-treated control promoter; #, p 0.05 versus its own control.
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inhibited by NECA, whereas EGR-1 reporter activity was not
affected by either treatment.
To further analyze the role of HIF1 and Sp1, previously iden-
tified as key transcription factors by site-directed mutations of
proximal binding sites, and the role of C/EBP, which possesses
several putative binding sites on the pfkfb3 promoter (Fig. 4B),
we used an shRNAor siRNAapproach to diminish their expres-
sion and explore the effects of this decrease on pfkfb3 promoter
activity. We first confirmed that specific shRNAs or siRNAs
diminished protein expression at least by 80% of control levels.
Then we observed (Fig. 5B) that reduced expression of HIF1
greatly decreased pfkfb3 induction by LPS and LPS/A2R ago-
nists, corroborating its key role in LPS-induced pfkfb3 expres-
sion. However, enhanced expression of pfkfb3 by A2R agonists
was still observed under these circumstances. In line with the
results of the site-directed mutagenesis experiments, reduced
Sp1 expression clearly blocked the A2R agonist-dependent
enhancement of the pfkfb3 promoter activity, whereas basal
and LPS-induced pfkfb3 promoter activity levels were slightly
up-regulated. However, overexpression of Sp1 increased pfkfb3
promoter activity (supplemental Fig. 3). Reduced expression of
C/EBP (Fig. 5B) or C/EBP (data not shown) also diminishes
pfkfb3 induction by LPS and LPS/A2R agonists. Nevertheless,
we have not observed changes in the pfkfb3 promoter activity
after mutation of a C/EBP-binding site (855 nucleotides)
(data not shown). However, other putative C/EBP-binding sites
could be responsible for its effect; moreover, an indirect effect
could be involved as well.
We analyzedHIF1, C/EBP, and Sp1 expression in macro-
phages activated with LPS in the presence or in the absence of
A2 receptor agonists. As shown in supplemental Fig. 4, HIF1
mRNA and protein levels increased after LPS treatment. Aden-
osine or NECA exerted little effect by themselves on HIF1
expression, but both A2 agonists cooperated with LPS to
increase it. Similarly, LPS induced the expression of C/EBP
and C/EBP proteins, and this induction was further enhanced
by NECA 3 h after LPS treatment. At this time, using macro-
phage nuclear extracts, we also observed a cooperative effect
between LPS andNECA to trigger protein binding to a consen-
sus C/EBP sequence. Expression of C/EBP and C/EBP pro-
teins also increased pfkfb3 promoter activity (supplemental
Fig. 5).
However, in agreement with previously reported results (38,
39), we did not observe changes in Sp1 expression after macro-
phage activation with LPS in the presence or in the absence of
A2 agonists (Fig. 5C). As the activity of Sp1 can bemodulated by
post-translational modifications, we evaluated whether its
phosphorylation state changed in the course of macrophage
activation with LPS or A2 receptor agonists. As shown in Fig.
5C, similar Sp1 Ser(P) content was detected in all conditions.
Thus, other post-translational modifications, different from
phosphorylation, are probably involved in Sp1 activation (40).
A2A Receptors Are Essential for LPS and Adenosine Induction
of pfkfb3 Expression—To assess the role of both A2A and A2B
adenosine receptors in pfkfb3 induction, we evaluated the
expression of this gene in the presence of ZM 241385 or
MRS1754, which are A2A andA2B receptor antagonists, respec-
tively. Both inhibitors diminished the induction of pfkfb3 by a
combination of LPS and A2R agonists by around 40%. Surpris-
ingly, both inhibitors also affected to a similar extent the induc-
tion of pfkfb3 by LPS alone, arguing for a role of A2 receptors in
the induction of this gene by LPS (supplemental Fig. 6). To
further evaluate the role of these receptors, we overexpressed
each of them in Raw 264.7 cells along with the largest pfkfb3
FIGURE 5. Analysis of the transcription factors involved in pfkfb3 induction by LPS and A2 receptor agonists. A, transcriptional activity of reporter
constructs carrying binding sites for HIF1, NFB, C/EBP, SP1, or EGR-1 transfected in Raw 264.7 cells stimulated with LPS, NECA, or both. Results represent the
mean S.D. of at least three independent experiments. *,p 0.05 versus control; #,p 0.05 versus LPS treatment. B, analysis ofpfkfb3promoter activity in Raw
264.7 cells transfected with control, HIF1, cEBP shRNAs, or Sp1 siRNA and stimulated for 18 h with LPS and/or NECA. All transfection experiments were
performed in triplicate. Results represent themean S.D. of at least three independent transfection experiments. *, p 0.05 versus control shRNA or siRNA. In
each case, efficiency of shRNAs knockdown is shown byWestern blot (Wblot). C, analysis byWestern blot of Sp1 expression and phosphorylation in Raw 264.7
cells activated by LPS, NECA, or both for 6 h. Total cell proteins (1 mg) were immunoprecipitated (IP) with anti-Sp1 antibody and revealed afterward with
anti-Ser(P) or anti Sp1 antibodies. A representative experiment out of three is shown.
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promoter construct. As shown in Fig. 6A, expression ofA2A, but
not of A2B receptor, in the absence of any exogenous stimula-
tion, increased the promoter activity by about 5-fold. Treat-
ment with NECA did not increase further the activity of the
pfkfb3 promoter in cells transfected with the A2A receptor, but
increased its activity in cells overexpressing the A2B receptor.
These differences are probably related to the different affinities
of each receptor for adenosine (0.7 M for A2A and 24 M for
A2B (35)) and suggest that endogenous adenosine production
by macrophages is sufficient to activate A2A but not A2B recep-
tors. Induction of the pfkfb3 promoter by LPS is also stronger
when A2A rather than A2B is overexpressed, but as observed
previously in the absence of LPS, treatment with NECA was
unable to further increase luciferase activity by A2A, although it
increased pfkfb3 promoter activity in cells transfected with the
A2B receptor.
In an additional approach to clarify the role of A2A and A2B
receptors in pfkfb3 induction by LPS and adenosine, we tran-
siently transfected Raw 264.7 cells with the3,566 pfkfb3 pro-
moter construct and A2A or A2B receptor shRNAs. As shown in
Fig. 6B, the LPS-induced increase in pfkfb3 promoter activity
diminished in the presence of A2A shRNA, but it was not
affected by A2B shRNA. However, again, both A2A andA2B
shRNAs diminished the effects caused by adenosine or NECA.
To confirm the role of A2A receptor in the LPS-dependent
induction of pfkfb3 gene expression, we generated stably trans-
fected Raw 264.7 cells with a control or with an A2A receptor
shRNA to decrease its expression. As shown in Fig. 6C, dimin-
ished A2A receptor expression levels resulted in reduced pfkfb3
expression after macrophage activation by LPS. Taken
together, these results suggest that, although both A2A and A2B
receptors are implicated, the A2A receptor is essential for the
induction of pfkfb3 expression by LPSwhen low concentrations
of adenosine are present in the medium. A2B receptors are less
relevant in this role, but they can further increase pfkfb3 expres-
sion when adenosine accumulates in stressful situations.
LPS Increases AMP Kinase Activity in Macrophages—Differ-
ent reports (41, 42) have shown that PFKFB3 activity can be
modulated by phosphorylation at Ser-461 by the AMP-acti-
vated protein kinase (AMPK). AMPK is activated by phosphor-
ylation when the AMP/ATP ratio is elevated and can switch on
catabolic pathways by different mechanisms, including phos-
phorylation of metabolic enzymes (43), as described for the
PFKFB3 isozyme (41). To evaluate the possible contribution of
LPS and adenosine toward the activation of AMPK tomodulate
PFKFB3 isozyme activity, we analyzed AMPK phosphorylation
and expression in macrophages activated by LPS and/or aden-
osine. As shown in Fig. 7A, AMPK phosphorylation increases
over the control levels in long term LPS-activatedmacrophages
(8–24 h). When AMPK expression was analyzed, higher levels
of protein could be observed after LPS treatment. No differ-
ences between LPS and LPS/adenosine conditions were
observed. These data lead us to conclude that increased AMPK
activity, due to increased AMPK expression and phosphoryla-
tion, is present in long term activated macrophages, which
FIGURE 6. A2A and A2B receptors collaborate to increase LPS-induced pfkfb3 expression. A, overexpression of A2A or A2B receptors increases pfkfb3
promoter activity inmacrophages. Raw264.7 cellswere cotransfectedwith3,566-pfkfb3-Luc andA2AorA2B receptor expressionvectors and treatedwith LPS,
NECA, or both for 18 h. A -galactosidase expression vector was used as a transfection control. All experiments were performed in triplicate. Results represent
themean S.D. of the luciferase activity determined in at least three independent transfection experiments. *, p 0.05 versus control transfection; #, p 0.05
versus NECA treatment. B, effect of A2A or A2B receptor shRNAs in the activity of the 3,566-pfkfb3 promoter construct. Raw 264.7 cells were transiently
cotransfected with3,566-pfkfb3-Luc and control or A2A or A2B receptor shRNAs and treated with LPS, NECA, or both for 18 h. A -galactosidase expression
vector was used as a transfection control. All experiments were performed in triplicate. Results represent themean S.D. of the luciferase activity determined
in at least three independent transfection experiments. *, p  0.05 versus control transfection. C, expression of A2A receptors and pfkfb3 mRNAs in stably
transfected Raw264.7 cells expressing control or A2A receptor shRNAs and activated or notwith LPS or LPS/NECA. *, p 0.05 versus control shRNA. In each case
efficiency of shRNAs knockdown is shown by Western blot.
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could contribute also to increased PFKFB3 activity and Fru-
2,6-P2 accumulation in these cells.
Increased Lactate Production and ATP Supply in Macro-
phages Activated by LPS and Adenosine—As the glycolytic flux
is mainly controlled by 6-phosphofructo-1-kinase (9), and the
main consequence of enhanced glycolytic function is an
increase in lactate production, we analyzed this metabolite in
macrophages activated by LPS and adenosine. As reported pre-
viously (5), increased levels of lactate are observed in LPS-acti-
vatedmacrophages (Fig. 7B). Statistically significant higher lac-
tate levels, over those reached with LPS alone, were observed
after treatment with adenosine.
We also analyzed the ATP levels in activated macrophages.
In agreement with previous data (34), decreased ATP levels
were observed during the first hours after LPS treatment (data
not shown). However, long term macrophage activation with
LPS (from 12 to 36 h) resulted in increased ATP levels (Fig. 7B).
This increase was enhanced by adenosine. Thus, it appears that
adenosine cooperates with macrophage-activating signals to
increase energy supply, permitting macrophage long term
activity. Along this line, besides PFKFB3, expression of other
glycolytic enzymes, such as PGK and the glucose transporter
Glut1, is also increased by LPS and A2 receptor agonists, as
shown in Fig. 7C.
DISCUSSION
Macrophages and phagocytic cells accomplish their defen-
sive roles in hostile environments, poor in oxygen and rich in
free radicals able to block electron transport in mitochondria.
In these conditions, ATP supply by anaerobic glycolysis is an
essential source of energy for these cells. In this work, we show
that molecules present in the macrophage microenvironment,
particularly adenosine, cooperatewith some pathogen-induced
activation signals to increase the glycolytic flux through the
induction of pfkfb3 expression and PFKFB3 isozyme activity.
Our results identify, for the first time, pfkfb3 as a gene synergis-
tically up-regulated by LPS and adenosine, which produces a
synergistic effect on the expression and activity of PFKFB3.We
have analyzed themolecular mechanisms underlying the coop-
erative induction of pfkfb3 expression by LPS and adenosine,
and we concluded that different processes are implicated. First,
LPS induces the expression of A2A and A2B receptors, increas-
ing the sensitivity of the macrophage to adenosine. Second,
both LPS and adenosine increase the expression of HIF1,
C/EBP, and C/EBP, which are key transcription factors for
pfkfb3 expression. Third, adenosine increases Sp1 activation,
which cooperatively up-regulates pfkfb3 expression. Moreover,
long term LPS treatment induces AMPK activation, favoring
phosphorylation of PFKFB3 at Ser-461, and thus increasing its
kinase activity. Therefore, increased expression and phos-
phorylation of the PFKFB3 isozymemust be responsible for the
increased levels of Fru-2,6-P2 and glycolytic rate observed in
activated macrophages in the presence of adenosine.
Bacterial LPS and inflammatory cytokines have been re-
ported to modify the expression of adenosine receptors,
although somewhat different results are reported in the litera-
ture. A small (2-fold) increase in the expression of the A2A
FIGURE 7. Adenosine and LPS cooperate to increase the glycolytic flux and ATP production inmacrophages. A, analysis by Western blot of pAMPK and
AMPK levels inmacrophages activatedwith LPS (100 ng/ml) and/or adenosine (100M) or NECA (10M) for different times. Results represent themean S.D.
of at least three independent experiments. Tubulin expression is used as a reference. *, p 0.05 versus control condition. A representativeWestern blot is also
shown. B, determination of lactate production (upper panel) and intracellular ATP levels (lower panel) in macrophages activated as described previously for 12
or 24 h, respectively. Results represent themean S.D. of at least three independent experiments. *, p 0.05 versus control; #, p 0.05 versus LPS treatment.
C, expression analysis by RT-PCR of different genes implicated in glucose metabolism in macrophages stimulated for 4 h with LPS and/or NECA. Results
represent the mean S.D. of at least three independent experiments. PGK, phosphoglycerate kinase.
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receptor mRNA has been reported in the case of humanmono-
cytic cell lines (44). However, Murphree et al. (37) reported
greater than 100-fold increase in A2A receptor expression in
human or mice macrophages, in addition to a concomitant up-
regulation of the A2B receptor. Our results agree with this last
work in that macrophage activation by LPS significantly
increasesA2A andA2B adenosine receptors.On the contrary, A1
and A3 receptors are down-regulated by proinflammatory sig-
nals. A2A and A2B receptors increase cAMP levels, whereas A1
and A3 exert the opposite effect (35); thus macrophage activa-
tion by LPS causes an adenosine receptor isoform expression
pattern switch that can selectivelymodify themacrophage phe-
notype. We have also analyzed the molecular mechanism
responsible for this effect and unveiled, by using genetic
approaches, that NFB is a key transcription factor in LPS-
induced A2A receptor expression, whereas IRF3 is not impli-
cated. On the contrary, A2B receptor expression depends on
IRF3 and is less affected by NFB. These results suggest that
different Toll receptor agonists would induce different adeno-
sine receptor expression patterns depending on the main tran-
scription factors activated by the similar, but not identical, Toll
receptor signaling pathways, thusmodifying in this waymacro-
phage sensitivity to adenosine.
One of the more surprising findings of this work is that the
endogenous production of adenosine by activated macro-
phages functions as a second messenger in the LPS signaling
pathway leading to increasedpfkfb3 expression.A role for aden-
osine in the induction of IL-10 synthesis by Escherichia coli has
also been described (45). Therefore, increasing evidence shows
that endogenous adenosine production by macrophages medi-
ates part of the effects triggered by LPS on macrophage gene
expression.
In the last decade, multiple evidence has shown that adeno-
sine, A2A, and, to a lesser extent, A2B receptors exert a crucial
anti-inflammatory and immunosuppressive effect (reviewed in
Refs. 21, 35), essential in limiting macrophage activity and pro-
tecting surrounding tissues of collateral damage during infec-
tion. In vivo genetic experiments have confirmed the anti-in-
flammatory role of A2 receptors (26). Our results are consistent
with these observations, as they show that adenosine dimin-
ishes TNF expression and increases iNOS synthesis, which
also agrees with previous reports (46). In this context, we have
observed increased pfkfb3, PGK, and Glut1 gene expression
(Fig. 7). Thus adenosine, besides diminishingmacrophage acti-
vation, seems to cooperate with LPS to increase the expression
of proteins implicated in glucose transport and catabolism.
Among them, PFKFB3 is especially relevant due to the essential
role that the metabolite it produces, Fru-2,6-P2, plays in the
control of the glycolytic flux (11).
Our analysis of the pfkfb3 promoter activity and studies per-
formed with specific shRNAs or siRNAs identified HIF1 as a
key transcription factor implicated in LPS induction (Fig. 6).
HIF1 is an essential mediator allowing cell adaptation to low
oxygen levels. Cramer et al. (5), using conditional gene target-
ing deletion of HIF1 in the myeloid cell lineage of mice, have
clearly shown that this transcription factor is essential for
macrophage energy supply and function and for the orchestra-
tion of the inflammatory response in vivo. Although hypoxia is
the main cause of HIF1 activation, an increasing body of evi-
dence indicates that this transcription factor may also be up-
regulated by nonhypoxic stimuli. Indeed, cytokines, such as
TNF and IL-1, and inflammatory mediators, such as NO,
have been shown to increase HIF1 levels during normoxia
(47–49). This induction involves transcriptional (47) and post-
transcriptional mechanisms for HIF1 stabilization (50, 51). In
macrophages, adenosine, through its A2 receptor, increases
HIF1 levels in a process depending on protein kinase C and
PI3K pathways, which involve transcriptional and, to a large
extent, translational mechanisms (52). HIF1 has been previ-
ously related to adenosine and LPS cooperation in the expres-
sion of VEGF (25). Our results extend these observations and
show the essential role played by HIF1 in LPS and adenosine-
induced expression of pfkfb3 in macrophages.
C/EBP transcription factors play a fundamental role in the
process of macrophage differentiation and in the regulation of
different functions in activated macrophages (53–55). Toll-4
receptors increase C/EBP expression, favoring the transcrip-
tion of multiple proinflammatory genes, such as IL-6, TNF,
and iNOS (56). C/EBP is also induced after LPS treatment by a
mechanism depending on NFB (57). Indeed, it has been
recently described that C/EBP cooperates withNFB tomain-
tain long term gene expression in persistent Toll receptor sig-
naling (57). Our results show that LPS and adenosine cooperate
to increase C/EBP and C/EBP expression and that all these
proteins are able to increase pfkfb3 promoter activity. Expres-
sion of anti-inflammatory cytokines, such as IL-10, induced by
LPS, is mediated by C/EBP (39, 45), and this process depends
on the expression of A2 receptors (45). Transduction through
these receptors implicates the activation of cAMP-dependent
protein kinaseA,which phosphorylates the transcription factor
CREB (58). Recently, it has been described that CREB increases
the expression of C/EBP (45). Activation of CREB has been
also related to the strong anti-inflammatory properties of A2
receptors by competingwithNFB and other transcription fac-
tors for the important cofactor CREB-binding protein.
Induction of HIF1 and C/EBP and C/EBP activity by
adenosine in activated macrophages has been previously re-
ported to explain the cooperative effect of adenosine and bac-
terial components in VEGF and IL-10 expression, respectively
(25, 45). However, in this work we show, for the first time, that
the transcription factor Sp1 is also implicated in the regulation
of gene expression by adenosine (Fig. 6). Sp1 was thought to
servemainly as a constitutive activator for housekeeping genes,
but growing evidence shows that post-translational modifica-
tions can modulate its transcriptional activity (reviewed in Ref.
40). Sp1 can be phosphorylated by various kinases at different
sites. Decreased Sp1 phosphorylation has been related to the
expression of IL-21 receptor in activated T cells (59). On
the contrary, increased expression of apolipoprotein A-I by the
action of Sp1 seems to be modulated in its phosphorylation by
protein kinase A and C, among others (60, 61). The influence of
phosphorylation on Sp1 activity is not completely understood.
Although it was tempting to speculate that activation of protein
kinase A after adenosine receptor triggering is implicated in the
increased Sp1 activity observed in macrophages activated with
LPS and A2 receptor agonists, our results discard this hypoth-
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esis, because we observed that the increased Sp1 activity does
not appear to depend on Ser phosphorylation. Further work is
needed to clarify the post-translational modifications that
explain these molecular events.
Expression of pfkfb3 occursmainly in proliferative and trans-
formed cells (13, 14). Previous reports have also described its
expression in human and mouse macrophages, astrocytes, and
monocytes (14, 15, 62). Besides, there is evidence of pfkfb3 up-
regulation by hypoxia, serum, insulin, and proinflammatory
molecules (14, 17, 62, 63). In addition to transcription, PFKFB3
isozyme activity is regulated by phosphorylation by AMPK at
Ser-461, which increases its Vmax without affecting its Km val-
ues (11). Our results show that expression of the pfkfb3 gene is
highly up-regulated inmacrophages activated by LPS and aden-
osine agonists by increasing the transcriptional activity of its
promoter. In addition, our results show increased levels of acti-
vated and phosphorylated AMPK in long term LPS-activated
macrophages, which further increase PFKFB3 activity through
AMPK-dependent phosphorylation in those cells. This effect
could be related to NO accumulation, as it has been described
in astrocytes, inwhich increasedNO levels results inmitochon-
drial inhibition and AMPK activation (15). Increased glycolytic
flux originated by the NO/AMPK induction of PFK2.3 activity
increases, in turn, the resistance of astrocytes to apoptosis (15).
Elevated glycolysis also seems to be essential for the activation
of other immune cells, such as T lymphocytes. Although the
energetic yield of glycolysis ismuch smaller than that of glucose
oxidation in the mitochondria, in conditions of unlimited glu-
cose supply, glycolysis producesATP substantially faster, so the
stimulation of glucose uptake and glycolysis is also essential for
proper T cell activation, and a defective energy supply results in
the death of T cells by apoptosis (64). Therefore, we can
hypothesize that the up-regulation of PFKFB3 isozyme expres-
sion observed in activated macrophages could also favor their
viability in the inflammatory microenvironment. Along this
line, a recent work reports that diminishing PFKFB3 expression
increasesmacrophage apoptosis and limits macrophage activa-
tion (62).
In summary, our results demonstrate an important role for
adenosine signaling in inflammation. Besides its crucial anti-
inflammatory and immunosuppressive effects, essential in lim-
itingmacrophage activity and protecting surrounding tissues of
collateral damage, adenosine, through A2 receptor activation,
cooperates with signaling pathways triggered by some patho-
gen components to increase glycolytic flux and energy supply in
macrophages, favoring the expression and activation of the key
glycolytic isozyme PFKFB3. This process could be essential in
protecting the viability of macrophages to develop their long
term defense and reparative functions.
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